Search
Menu
Home
HTB
2019
August
HTB
August 2019
Contents
Editorial
HTB 23 August 2019 online: second reports from IAS 2019
Special reports
Fit for purpose: antiretroviral treatment optimisation July 2019
Conference reports
10th IAS Conference on HIV Science (IAS 2019) in Mexico City
Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution
Switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance
Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study
Dolutegravir for younger children: results from the ODYSSEY trial
PK advantages of TAF/FTC over TDF/FTC for HIV PrEP might compensate for low adherence: sub-analysis of DISCOVER study
Antiretrovirals
Cabotegravir/rilpivirine long-acting injectable HIV drugs submitted to EMA
PDFs
23 August 2019 vol 20 no 10
HTB RSS
Early access
Future PrEP and updated lenacapavir studies with case details from PURPOSE 2
21 November 2024
Glasgow HIV Congress 2024
10 November 2024
Unheard: The medical practice of silencing – by Dr Rageshri Dhairyawan
9 November 2024
Bipolar disorder in people living with HIV
1 November 2024
All early access reports
Current issues
November 2024
October 2024
September 2024
Back issues
Special report
HTB news: i-Base changes during 2024
1 November 2024
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate